Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Videos from this campaign

Stephanie Lheureux, MD, PhD,Princess Margaret Cancer Centre (PMCC).
Illumina Booth at UK Festival of Genomics & Biodata

Content from this campaign

Diversity & Inclusion

Video: Increasing Genomic Capability in the United Arab Emirates
Emirati scientists, clinicians, and dignitaries attended the opening of the Illumina Solutions Center in Dubai on November 8. The new state-of-the-art facility will expand genomics capabilities and build local expertise in genomics to advance and deliver precision medicine to patients at scale.

Health & Healthcare

Addressing the Shortage of Genetic Counselors With Software
Nearly everyone is a carrier for some kind of genetic disorder. (Probably even you.) Being a carrier means you inherited an abnormal copy of a gene from one parent, but you show no symptoms because you got a normal copy of that gene from your other parent.

Innovation & Technology

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States
Illumina announced a new research test for genitourinary pathogen and antimicrobial resistance (AMR) identification. The Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP) applies precision metagenomics to detect and quantify pathogens.

Health & Healthcare

Rarebase Is on the Hunt for Therapeutic Opportunities
San Francisco Bay Area residents Jainu and Shruti Jogani had their newborn daughter, Reyna, at home for nearly three weeks when they noticed her exhibiting seizure-like symptoms—episodes so quick they weren’t able to capture them on video.

Health & Healthcare

Can Genomics Stop the World's Leading Cause of Death?
For decades, cardiovascular disease has remained the number-one cause of death. In 2019 alone, nearly 18 million people around the world died from cardiovascular diseases (CVDs), which include disorders such as coronary heart disease, heart failure, and cerebrovascular disease. Most of these deaths result from heart attack or stroke.

Health & Healthcare

Illumina and GenoScreen Partner To Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
Illumina announced a partnership to accelerate progress to end tuberculosis (TB) worldwide. The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB (MDR-TB).

Innovation & Technology

Tracking COVID-19 With Dust at the Ohio State University
When COVID-19 hit, most of The Ohio State University—home of the Buckeyes in the state capital of Columbus—shut down. But the Applied Microbiology Services Laboratory (ASML) within its Infectious Diseases Institute (IDI) stayed open.

Health & Healthcare

Australia Begins a Big Push To Sequence Underserved Populations
Australia’s Centre for Population Genomics (CPG), a collaboration between the Garvan Institute of Medical Research and the Murdoch Children’s Research Institute, has launched a new initiative to engage diverse communities in genomic research.

Health & Healthcare

Illumina Launches Strategic Research Collaboration With AstraZeneca To Accelerate Drug Target Discovery
Illumina announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise.

Health & Healthcare

How Comprehensive Genomic Profiling Is Helping Cancer Patients Today
The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensive genomic profiling (CGP). CGP is a next-generation sequencing (NGS) approach that uses a single test to assess hundreds of genes—including relevant cancer biomarkers, as established in medical guidelines and clinical trials—for tumor therapy guidance.
Illumina logo

More from Illumina

  1. Community
    By sharing our time, talent, and technology, we aim to inspire, support, and empower our communities, our employees, and the next generation.

  2. Access
    Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in...

  3. Business
    At Illumina, the faster we can innovate, the more lives we can help save. As a genomics pioneer, we have proven through focused and continued...

  4. Environment
    We are committed to integrating environmental stewardship into the way we operate. We recognize the importance of the environment in creating a...

  5. Operating Responsibly
    Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...

  6. People
    Harnessing the world’s best talent and giving them the opportunity to thrive allows us to make world-changing leaps in human health and beyond. Our...